{"denoms":[{"counts":[{"groupId":"BG000","value":"322"},{"groupId":"BG001","value":"321"},{"groupId":"BG002","value":"643"}],"units":"Participants"}],"groups":[{"description":"Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week cycle for up to 18 cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an adverse event requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\\^2 every 3 weeks \\[Q3W\\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.","id":"BG000","title":"Pembrolizumab + Paclitaxel ± Bevacizumab"},{"description":"Participants receive placebo via IV infusion on Day 1 of each 6-week cycle for up to 18 cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an adverse event requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\\^2 every 3 weeks \\[Q3W\\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.","id":"BG001","title":"Placebo + Paclitaxel ± Bevacizumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.7","value":"61.6"},{"groupId":"BG001","spread":"9.9","value":"60.6"},{"groupId":"BG002","spread":"10.3","value":"60.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"322"},{"groupId":"BG001","value":"321"},{"groupId":"BG002","value":"643"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"98"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"261"},{"groupId":"BG001","value":"255"},{"groupId":"BG002","value":"516"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"29"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"130"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"207"},{"groupId":"BG001","value":"217"},{"groupId":"BG002","value":"424"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"29"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"44"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"235"},{"groupId":"BG001","value":"236"},{"groupId":"BG002","value":"471"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"172"}],"title":"No"}]}],"description":"For the participant to receive bevacizumab in the study (yes versus no).","paramType":"COUNT_OF_PARTICIPANTS","title":"Investigator Choice to Use Bevacizumab","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"177"}],"title":"CPS <1"},{"measurements":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"132"},{"groupId":"BG002","value":"265"}],"title":"CPS 1 to <10"},{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"201"}],"title":"CPS ≥10"}]}],"description":"The Programmed Cell Death-Ligand 1(PD-L1) Combined Positive Score (CPS) status indicates tumor PD-L1 positivity using both tumor cells and inflammatory cells that are positive for PD-L1 by immunohistochemistry (IHC). The number of participants with CPS \\<1, CPS 1 to \\<10, and CPS ≥10 at baseline is presented. Participants with a CPS \\<1 were classified as PD-L1 negative and participants with a CPS≥1 were classified as PD-L1 positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"59"}],"title":"United States (US)"},{"measurements":[{"groupId":"BG000","value":"149"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"300"}],"title":"European Union (EU)"},{"measurements":[{"groupId":"BG000","value":"143"},{"groupId":"BG001","value":"141"},{"groupId":"BG002","value":"284"}],"title":"Rest of World (ROW)"}]}],"description":"Participants were stratified by region of enrollment; United States (US), versus European Union, versus Rest of World (ROW).","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"}]}